{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:23:09Z","timestamp":1769944989766,"version":"3.49.0"},"reference-count":43,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moderate-to- severe AD receiving dupilumab or placebo, plus low-potency topical corticosteroids. Post hoc analyses were performed on the full analysis set (FAS) and a subset of patients with Investigator\u2019s Global Assessment score &gt;\u20091 at week 16. The primary outcome was the proportion of patients at week 16 achieving a composite endpoint encompassing clinically meaningful changes in AD signs, symptoms and QoL: \u2265 50% improvement in Eczema Area and Severity Index; and\/or \u2265 4-point reduction in worst scratch\/itch numerical rating scale; and\/or \u2265 6-point reduction in Children\u2019s Dermatology Life Quality Index\/Infants\u2019 Dermatitis Quality of Life Index. Significantly more patients receiving dupilumab vs placebo achieved the composite endpoint in both the FAS (77.7% vs 24.6%, p\u2009&lt;\u20090.0001) and subgroup (68.9% vs 21.5%, p\u2009&lt;\u20090.0001). Dupilumab provided rapid and significant, clinically meaningful improvements in AD signs, symptoms, and QoL in the overall group and subgroup of patients who did not achieve clear or almost clear skin at week 16.<\/jats:p>","DOI":"10.2340\/actadv.v104.13467","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T13:32:31Z","timestamp":1707744751000},"page":"adv13467","source":"Crossref","is-referenced-by-count":8,"title":["Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator\u2019s Global Assessment: A Post Hoc Analysis of a Phase 3 Trial"],"prefix":"10.2340","volume":"104","author":[{"given":"Michael J.","family":"Cork","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy","family":"Prescilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"48786","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol 2021; 126: 417-428.e2.","DOI":"10.1016\/j.anai.2020.12.020"},{"key":"48787","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.anai.2020.12.020","DOI":"10.1016\/j.anai.2020.12.020"},{"key":"48788","doi-asserted-by":"crossref","unstructured":"Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel) 2019; 6: 133.","DOI":"10.3390\/children6120133"},{"key":"48789","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/children6120133","DOI":"10.3390\/children6120133"},{"key":"48790","doi-asserted-by":"crossref","unstructured":"Ramirez FD, Chen S, Langan SM, Prather AA, McCulloch CE, Kidd SA, et al. Association of atopic dermatitis with sleep quality in children. JAMA Pediatr 2019; 173: e190025.","DOI":"10.1001\/jamapediatrics.2019.0025"},{"key":"48791","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamapediatrics.2019.0025","DOI":"10.1001\/jamapediatrics.2019.0025"},{"key":"48792","doi-asserted-by":"crossref","unstructured":"Barbarot S, Silverberg JI, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. J Pediatr 2022; 246: 220-226.e5.","DOI":"10.1016\/j.jpeds.2022.04.027"},{"key":"48793","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jpeds.2022.04.027","DOI":"10.1016\/j.jpeds.2022.04.027"},{"key":"48794","doi-asserted-by":"crossref","unstructured":"Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71: 327-349.","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"48795","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2014.03.030","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"48796","doi-asserted-by":"crossref","unstructured":"Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014; 111: 5147-5152.","DOI":"10.1073\/pnas.1323896111"},{"key":"48797","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1073\/pnas.1323896111","DOI":"10.1073\/pnas.1323896111"},{"key":"48798","doi-asserted-by":"crossref","unstructured":"Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014; 111: 5153-5158.","DOI":"10.1073\/pnas.1324022111"},{"key":"48799","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1073\/pnas.1324022111","DOI":"10.1073\/pnas.1324022111"},{"key":"48800","doi-asserted-by":"crossref","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130-139.","DOI":"10.1056\/NEJMoa1314768"},{"key":"48801","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1314768","DOI":"10.1056\/NEJMoa1314768"},{"key":"48802","doi-asserted-by":"crossref","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.","DOI":"10.1056\/NEJMoa1610020"},{"key":"48803","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1610020","DOI":"10.1056\/NEJMoa1610020"},{"key":"48804","doi-asserted-by":"crossref","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303.","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"48805","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"48806","doi-asserted-by":"crossref","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 44-56.","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"48807","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"48808","doi-asserted-by":"crossref","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2022; 400: 908-919.","DOI":"10.1016\/S0140-6736(22)01539-2"},{"key":"48809","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2","DOI":"10.1016\/S0140-6736(22)01539-2"},{"key":"48810","doi-asserted-by":"crossref","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020; 83: 1282-1293.","DOI":"10.1016\/j.jaad.2020.06.054"},{"key":"48811","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054","DOI":"10.1016\/j.jaad.2020.06.054"},{"key":"48812","doi-asserted-by":"crossref","unstructured":"Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol 2016; 74: 288-294.","DOI":"10.1016\/j.jaad.2015.09.062"},{"key":"48813","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2015.09.062","DOI":"10.1016\/j.jaad.2015.09.062"},{"key":"48814","doi-asserted-by":"crossref","unstructured":"Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema\/dermatitis clinical trials (HOME). Br J Dermatol 2014; 171: 1318-1325.","DOI":"10.1111\/bjd.13237"},{"key":"48815","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.13237","DOI":"10.1111\/bjd.13237"},{"key":"48816","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Simpson EL, Ardeleanu M, Tha\u00e7i D, Barbarot S, Bagel J, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol 2019; 181: 80-87.","DOI":"10.1111\/bjd.17791"},{"key":"48817","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.17791","DOI":"10.1111\/bjd.17791"},{"key":"48818","doi-asserted-by":"crossref","unstructured":"Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol 2020; 21: 119-131.","DOI":"10.1007\/s40257-019-00478-y"},{"key":"48819","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-019-00478-y","DOI":"10.1007\/s40257-019-00478-y"},{"key":"48820","doi-asserted-by":"crossref","unstructured":"Siegfried EC, Cork MJ, Katoh N, Zhang H, Chuang C-C, Thomas RB, et al. Dupilumab provides clinically meaningful responses in children aged 6-11 years with severe atopic dermatitis: post-hoc analysis results from a phase III trial. Am J Clin Dermatol 2023; 24: 787-798.","DOI":"10.1007\/s40257-023-00791-7"},{"key":"48821","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-023-00791-7","DOI":"10.1007\/s40257-023-00791-7"},{"key":"48822","doi-asserted-by":"crossref","unstructured":"Paller A, Siegfried E, Marron SE, Clark M, DiBenedetti D, Nelson L, et al. Development and validation of a caregiver-reported numeric rating scale for measuring pruritus in children aged 6 months to < 6 years with atopic dermatitis. [abstract]. J Invest Dermatol 2022 Aug; 142:S25. doi: 10.1016\/j.jid.2022.05.154.","DOI":"10.1016\/j.jid.2022.05.154"},{"key":"48823","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2022.05.154","DOI":"10.1016\/j.jid.2022.05.154"},{"key":"48824","doi-asserted-by":"crossref","unstructured":"Simpson EL, de Bruin-Weller M, Bansal A, Chen Z, Nelson L, Whalley D, et al. Definition of clinically meaningful within-patient changes in POEM and CDLQI in children 6 to 11 years of age with severe atopic dermatitis. Dermatol Ther (Heidelb) 2021; 11: 1415-1422.","DOI":"10.1007\/s13555-021-00543-7"},{"key":"48825","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-021-00543-7","DOI":"10.1007\/s13555-021-00543-7"},{"key":"48826","unstructured":"Paller AS, Marron SE, Whalley D, Qin S, Chao J, Bansal A, et al. Clinically meaningful within-patient change threshold for the Children's Dermatology Life Quality Index and Infants' Dermatitis Quality of Life Index instruments in patients aged 6 months to < 6 years with atopic dermatitis [abstract]. Poster presented at the 2022 European Academy of Dermatology and Venereology (EADV) Annual Meeting; Sept 7-10, 2022; Milan, Italy."},{"key":"48827","doi-asserted-by":"crossref","unstructured":"De Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol 2018; 178: 1083-1101.","DOI":"10.1111\/bjd.16156"},{"key":"48828","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16156","DOI":"10.1111\/bjd.16156"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/13467\/45304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/13467\/45304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T13:32:40Z","timestamp":1707744760000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/13467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":43,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.13467","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,12]]}}}